Latest market price
16.03
-0.17-1.05%
OverviewShort InterestFilings
SMMTQT57Summit Therapeutics Inc.·NASDAQ
16.03-1.05%
TA
Loading chart...
Signal & projected range
Short-squeeze setupHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
JAZZ+3.92%$215.98TECH-0.07%$72.66BMRN+1.77%$58.51BBIO+5.97%$74.95NBIX-0.19%$146.10HALO-0.21%$130.91KYMR+3.29%$126.63TWST-11.92%$152.78
Snapshot
Index—P/E—EPS (ttm)-1.12Insider Own—Shs Outstand797.75MPerf Week3.62%
Market Cap12.79BForward P/E—EPS next Y-1.13Insider Trans0.65%Shs Float110.35MPerf Month-3.95%
Enterprise Value12.12BPEG—EPS next Q—Short Float37.06%Perf Quarter22.84%
Income-856.00MP/S—EPS this Y—Short Ratio6.76Perf Half Y-0.50%
Sales0.00P/B20.30EPS next Y—ROA-113.81%Short Interest40.90MPerf YTD-8.35%
Book/sh0.79P/C18.51EPS next 5Y—ROE-204.33%52W High29.23 -45.16%Perf Year-14.09%
Cash/sh0.87P/FCF—EPS past 3/5Y—ROIC-134.14%52W Low12.07 32.81%Perf 3Y752.66%
Dividend Est.—EV/EBITDA—Sales past 3/5Y—Gross Margin0.00%Volatility6.00% 5.28%Perf 5Y221.89%
Dividend TTM—EV/Sales—EPS Y/Y TTM—Oper. Margin0.00%ATR (14)0.93Perf 10Y35.27%
Dividend Ex-Date—Quick Ratio6.96Sales Y/Y TTM—Profit Margin0.00%RSI (14)50.72Recom2.35
Dividend Gr. 3/5Y—Current Ratio6.96EPS Q/Q63.16%SMA20-0.25%Beta-1.59Target Price29.33
Payout0.00%Debt/Eq0.03Sales Q/Q—SMA50-0.16%Rel Volume0.57Prev Close16.20
Employees265LT Debt/Eq0.03EarningsNov 02SMA200-0.91%Avg Volume6.11MPrice16.03
IPO DateMar 05, 2015Option/ShortYes / YesEPS/Sales Surpr.-2.04% —Net Debt/EBITDA—Volume3,488,525Change-1.05%
Analyst Ratings
DateActionAnalystRatingTarget
Oct-01-26ReiteratedBarclaysEqual Weight$16 → $20
Sep-29-26ReiteratedGoldman SachsBuy$41
Sep-29-26ReiteratedJefferiesBuy$15 → $30
Sep-09-26ReiteratedSummit Redstone Partners$12 → $25
Sep-09-26UpgradeJefferiesHold → Buy
Sep-08-26ReiteratedUBS$33
Aug-25-26ReiteratedSummit Redstone Partners$18 → $12
Aug-25-26UpgradeBernsteinUnderperform → Market Perform
Aug-12-26UpgradeLeerink PartnersUnderperform → Market Perform
Jul-24-26ReiteratedJefferiesHold$17 → $15
Latest News· Times ET
Oct-26-26
Oct-26-2612:05PM
Buy the Dip: 4 Stocks the Market Marked Down Too Far Ahead of Big Catalystsmarketbeat.com
07:30AM
Breakfast News: Science Strikes Back at Cancerfool.com
07:00AM
Lunit and Summit to evaluate pathology platform for tumour analysisYahoo
Oct-25-26
Oct-25-2612:00PM
Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Sgurufocus.com
11:52AM
Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study Conducted by Akeso in Chinabusinesswire.com
Oct-23-26
Oct-23-2609:26PM
Lunit and Summit Therapeutics Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Developmentprnewswire.com
04:37PM
Summit Therapeutics and Lunit Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Developmentbusinesswire.com
Oct-22-26
Oct-22-2611:50AM
Summit Expands Ivonescimab Development Into Biliary Tract Cancerzacks.com
06:00AM
Ivonescimab Data Sets across Multiple Tumor Types to Be Featured at ESMO 2026businesswire.com
Oct-21-26
Oct-21-2612:01PM
Can Expanding Ivonescimab Development Unlock SMMT's Growth Potential?zacks.com
08:42AM
Akeso Announces Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II/III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancerprnewswire.com
06:05AM
Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II / III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancerbusinesswire.com
02:07AM
Summit Therapeutics Announces Clinical Trial Collaboration With The ECOG-ACRIN Cancer Research Group To Evaluate Ivonescimab In A Phase II/III Study In Biliary Tract CancerBenzinga
Oct-19-26
Oct-19-2607:00AM
Summit Therapeutics Announces Opening of Global Phase II Study of Ivonescimab-Based Regimens in Advanced Clear Cell Renal Cell Carcinomabusinesswire.com
Oct-13-26
Oct-13-2608:59AM
Chip Stocks Slide as South Korea's KOSPI Plunges, J&J Sinks 6%: Stock Market TodayBenzinga
Company

Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
1/31/2019
Total Revenue
0000—————
Cost of Goods Sold Incl. D&A
0000—————
Gross Profit
0000—————
Selling, General and Administrative Excl. Other3075574824—————
Research and Development569538132455—————
Other Operating Expense-2-11-1—————
Operating Income-874-1,094-181-478—————
Interest Expense00916—————
Unusual Expense
—————————
Non-Operating Income (Expense)19151212—————
Net Income Before Taxes-856-1,080-177-482—————
Income Taxes
0000—————
Consolidated Net Income-856-1,080-177-482—————
Net Income From Continuing Operations-856-1,080-177-482—————
Net Income-856-1,080-177-482—————
EPS (Recurring)-1.12-1.44-0.25-0.78—————
EPS (Basic, Before Extraordinaries)-1.12-1.44-0.25-0.78—————
EPS (Diluted)-1.12-1.44-0.25-0.78—————
EBITDA-856-1,079-168-69—————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio
—————————
Gross Margin
—————————
Operating Margin
—————————
Net Margin
—————————
Shares Outstanding778748714620—————
Market Capitalization12,47113,08312,7451,618—————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$29.16$24.43$19.70$14.98$10.25● Close Price0.00M25.90M51.81M77.71M103.62MUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
DUGGAN ROBERT WCo-Chief Executive OfficerJun 12 '26Buy13.123,810,00049,987,200573,883,879Jun 12
Zanganeh MahkamCo-Chief Executive OfficerJun 12 '26Buy13.123,810,00049,987,200573,883,879Jun 12
Soni Manmeet SinghCOO and CFOJun 04 '26Buy14.4550,000722,2503,123,603Jun 04
DUGGAN ROBERT WCo-Chief Executive OfficerJun 04 '26Buy14.60100,0001,460,00025,824,474Jun 04
Zanganeh MahkamCo-Chief Executive OfficerJun 04 '26Buy14.60100,0001,460,00025,824,474Jun 04
Xia YuDirectorOct 21 '25Buy18.74533,6179,999,98332,057,147Oct 23
DUGGAN ROBERT WCo-Chief Executive OfficerOct 21 '25Buy18.7426,680499,98376,680Oct 23
Zanganeh MahkamCo-Chief Executive OfficerOct 21 '25Buy18.7426,680499,98376,680Oct 23
Zanganeh MahkamCo-Chief Executive OfficerSep 11 '25Buy18.075,00090,350556,093,090Sep 11
DUGGAN ROBERT WCo-Chief Executive OfficerSep 11 '25Buy18.075,00090,350556,093,090Sep 11
Zanganeh MahkamCo-Chief Executive OfficerSep 10 '25Buy17.68333,3945,894,406556,088,090Sep 11
DUGGAN ROBERT WCo-Chief Executive OfficerSep 10 '25Buy17.68333,3945,894,406556,088,090Sep 11
Zanganeh MahkamCo-Chief Executive OfficerMay 30 '25Option Exercise2.6474,545196,799555,754,696Jun 02
DUGGAN ROBERT WCo-Chief Executive OfficerMay 30 '25Option Exercise2.6474,545196,799555,754,696Jun 02
Zanganeh MahkamCo-Chief Executive OfficerApr 08 '25Option Exercise1.587,970,11012,592,774555,680,151Apr 09
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.